NCT07323056: Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage Ⅲ EGFR-mutant Non-small Cell Lung Cancer

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China. Phase: PHASE2. Conditions: EGFR-mutant Non-small Cell Lung Cancer, Potentially Resectable